The microdosing conversation is dominated by two camps. On one side, enthusiasts who treat it as a cognitive enhancer — a productivity tool, a biohack, a shortcut to flow states. On the other, skeptics who point to the research and say the effects are largely placebo. Both camps are missing something important.
What the controlled studies show
The controlled studies are clear on several points. Microdosing does not reliably enhance cognitive performance on standardized measures. The expectancy effects are real and significant — people who believe they’re microdosing report benefits regardless of whether they received an active dose. And the long-term safety data is still sparse.
The most methodologically rigorous study to date — Szigeti et al. (2021), a self-blinding citizen science trial — found no significant difference between microdose and placebo groups on any cognitive or wellbeing measure. Other controlled trials have produced similarly underwhelming results when it comes to the specific claims made by Silicon Valley microdosing culture: enhanced focus, greater productivity, sharper problem-solving.
This is important data. It should be taken seriously. But it does not tell the whole story.
What gets lost in the debunking
Here’s what gets lost in the debunking: the practice context matters enormously. The controlled studies necessarily strip microdosing of everything except the molecule — no intention-setting, no journalling, no embodied practice, no community. They measure whether a sub-perceptual dose of psilocybin, taken in isolation, produces measurable cognitive enhancement. When it doesn’t, the conclusion drawn is that microdosing “doesn’t work.”
But this frames the question in a way that already misses the point. It is like testing whether a meditation cushion reduces anxiety — and concluding, when the cushion alone does nothing, that meditation doesn’t work.
When microdosing is embedded in a broader framework of attention, intention, and reflection — when it is treated as a mindfulness practice rather than a supplement — something different happens. The question shifts from “does this substance work?” to “what does this practice reveal?”
The mindfulness connection
The research on mindfulness and psychedelics points to a genuine synergy. A 2019 study by Smigielski et al. found that psilocybin combined with meditation retreat produced significantly greater increases in self-dissolution, positive mood, and social connectedness than either psilocybin or meditation alone. The effects persisted at four-month follow-up.
This finding makes sense within the framework of enactive cognition. Both psychedelics and contemplative practice work by loosening habitual perceptual structures — the automatic, ego-centred patterns through which we ordinarily organize experience. Psychedelics do this pharmacologically, by temporarily relaxing the brain’s predictive priors. Contemplative practice does it attentionally, by training the capacity to notice without immediately grasping or interpreting.
When the two are combined, the loosening goes deeper and the capacity to notice what has loosened is more developed. The experience becomes more available for learning — not because the molecule is doing more, but because the practitioner is.
At the microdose level, this dynamic is subtler but no less real. A sub-perceptual dose does not produce dramatic perceptual shifts. What it can do — within a practice context — is create a slightly wider aperture of attention. A bit more space between stimulus and response. A gentle foregrounding of sensory detail that might otherwise pass unnoticed.
Whether this effect is pharmacological, expectancy-driven, or some combination is, frankly, less important than the question of what you do with it.
What a practice-based approach looks like
This is the approach we take at Psygaia. Our microdosing course is not built around dosing protocols and supplement stacks. It is built around attention — learning to notice what changes, what doesn’t, and what that tells you about your relationship to your own experience. The substance is a tool within a practice, not the practice itself.
In practical terms, this means:
Intention before ingestion
Each session begins with a clear question or intention — not a performance goal (“be more productive”) but an inquiry (“what am I not noticing?”). This anchors the practice in curiosity rather than optimization.
Structured observation
Participants maintain a journal tracking not just mood and energy but subtler dimensions: quality of attention, bodily sensation, relational dynamics, engagement with the natural world. The aim is developing the skill of noticing, not accumulating data.
Embodied practice
Microdosing sessions are paired with somatic practices — breathwork, movement, time in nature. These are not add-ons. They are the primary vehicle through which the subtle attentional shifts become available for integration.
Scheduled pauses
Regular non-dosing periods are built into the protocol, specifically so participants can observe the difference. What is the substance doing? What is the practice doing? What happens when you bring the same quality of attention without the molecule?
Community reflection
Weekly group sessions provide a container for sharing observations and learning from each other’s experience. This is where the practice deepens — not in isolation, but in relationship.
Reframing the question
The microdosing debate, as currently framed, asks the wrong question. “Does microdosing work?” assumes a supplement model — take the pill, get the result. The answer, under those terms, appears to be: not reliably, and possibly not at all beyond placebo.
But “does this practice cultivate greater awareness?” is a different question with a different answer. Contemplative traditions have explored this territory for millennia. The addition of a sub-perceptual psychedelic to a well-structured contemplative practice is not a shortcut or a hack. It is a specific method within a much larger inquiry into the nature of attention, perception, and how we inhabit the world.
The research supports this reframing. The most interesting microdosing data is not about cognitive performance. It is about the relationship between expectancy, attention, and experience — which is to say, it is about the mind itself. That is worth studying, and it is worth practising. Just not the way most people are currently doing it.
